Adjust in time: beware of the challenges Annex VI brings for labelling

prism_010819.jpg

Gordon Alexander and Simon Jones outline how imminent changes to EU clinical trial regulations will have major implications for labelling processes.

 ALREADY A REGISTERED USER? SIGN IN now

Subscribe (for free) to read this article

In order to read this article, you must be a Packaging Europe subscriber. By becoming a subscriber, you get access to unmissable exclusive content like this, as well as enhanced personalisation options. The good news is that it’s completely free and very simple to subscribe - click the button below to learn more.

—>